Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Regulatory

Diagnos talks regulatory progress for CARA

By The Northwire Desk — AI Analysis Jan 13, 2026 · 20:26 ADK · 0.33 Diagnos Inc
ADK · Price

Executive Summary

  • Diagnos Inc. announced formal submission of its AI platform CARA to the Saudi Food and Drug Authority (SFDA) for marketing approval.
  • The company is on track to file a formal application with Health Canada within the current quarter.
  • Following recent meetings, Diagnos clarified FDA 510(k) requirements, positioning the firm to pursue U.S. clearance.

Key Details

  • Saudi Arabia (SFDA): CARA has been formally submitted for marketing approval; no timeline disclosed for decision.
  • Canada (Health Canada): Active engagement ongoing; formal application expected to be filed in Q2 2026.
  • United States (FDA): Strategic meetings clarified specific 510(k) clearance requirements; next steps include preparation of submission documentation.
  • Strategic Importance: Management cites regulatory approvals as a “significant catalyst for commercial growth and shareholder value.”

Notable Quotes

"Navigating the regulatory landscape for medical AI requires precision and expertise. Our team is fully focused on meeting the rigorous standards of Canada, the U.S. and Saudi Arabia," – Andre Larente, CEO, Diagnos Inc.

Read the original news release →

More from Diagnos Inc

Jun 18, 2026 · 12:00

Cash-preserving debt settlement underscores ongoing liquidity constraints ahead of critical CARA regulatory milestones.

Financings Jun 16, 2026 · 09:15

Pre-revenue medical AI developer navigating regulatory hurdles while burning through cash reserves.

Regulatory Jun 05, 2026 · 10:00

DIAGNOS Inc. Awaits Health Canada Catalyst as Cash Runway Narrows Ahead of Dilutive Financing

Regulatory Apr 08, 2026 · 12:14

Regulatory timeline update keeps CARA on track, no surprise for investors

Production / Operations Mar 05, 2026 · 18:26

Diagnos to amend convertible debenture, warrant terms

Financings Mar 05, 2026 · 15:45

DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

Financings